Vivos Therapeutics regains compliance with Nasdaq shareholders' equity requirement
VVOS•Nasdaq confirmed Vivos Therapeutics met its $2.5 million minimum stockholders' equity requirement on October 20, 2026, after the company acquired interests in SOD Sciences. Failure to demonstrate compliance in its next periodic report could trigger delisting, subject to appeal.
1. Compliance restored
Nasdaq confirmed Vivos Therapeutics' compliance with the $2.5 million minimum stockholders' equity requirement on October 20, 2026, under Listing Rule 5550(b)(1). Compliance was restored following the acquisition of interests in SOD Sciences and its pseudohypoxia early-warning test.
2. Next reporting period
Failure to demonstrate compliance in the next periodic report could trigger delisting, subject to appeal to a Nasdaq Hearings Panel.
